Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on August 15, 2019. The report discloses the appointment of a new senior executive officer and the terms of the associated employment agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details rather than financial performance.
Material Changes
The primary material change reported is the appointment of Dov Elefant as Vice President and Chief Financial Officer, effective September 10, 2019. Mr. Elefant brings over 20 years of experience, most recently serving as CFO of Akari Therapeutics PLC.
Compensation and Employment Terms
- Base Salary: $315,000 annually.
- Target Bonus: 30% of base salary.
- Equity Grant: Option to purchase 90,000 shares of common stock, vesting annually over three years.
- Severance: Nine months of severance for dismissal without cause or resignation for good reason; twelve months if such events occur within twelve months following a change in control.
Investor Verification Checklist
- Verify the effective start date of the new CFO (September 10, 2019).
- Review the full Employment Agreement (Exhibit 10.1) for complete terms and conditions.
- Confirm the vesting schedule details for the 90,000 share option grant.
- Check the press release (Exhibit 99.1) for additional context on the leadership transition.